Melane Sampson, Author at BioTuesdays

Executive Moves

Laurie Glimcher joins ReAlta’s BOD

Closely held ReAlta Life Sciences has appointed immunologist Laurie Glimcher, MD, to its board of directors (BOD), effective immediately. Dr. Glimcher, widely renown for her work in cancer research, brings more than 35...

April 1, 2025

Feature

MaaT Pharma advancing next frontier biotherapeutics with microbiome-driven therapies

MaaT Pharma (EURONEXT:MAAT) is at the forefront of developing the world’s first full-ecosystem approach to restoring microbiome symbiosis in oncology, improving cancer patient survival through innovative, fecal-derived...

April 1, 2025

Developments

Kazia agrees to sell Cantrixil IP and trademark rights to Vivesto

Kazia Therapeutics (NASDAQ:KZIA) announced it will receive $1 million for the sale of all intellectual property (IP) and trademark rights of Cantrixil to Vivesto (Nasdaq Stockholm:VIVE). Vivesto licensed the exclusive...

March 31, 2025

Developments

Neural shares commence trading on Frankfurt Stock Exchange

Neural Therapeutics (CSE:NURL) announced that shares of the company have commenced trading on the Frankfurt Stock Exchange under symbol “M6B”. The company is developing therapeutics to address mental illnesses related...

March 31, 2025

Developments

Leap reports positive Phase 2 data of sirexatamab in MSS CRC

Leap Therapeutics (NASDAQ:LPTX) announced positive updated data from its Phase 2 study of sirexatamab (DKN-01), an anti-DKK1 monoclonal antibody, in combination with bevacizumab and chemotherapy, compared to bevacizumab...

March 26, 2025

Developments

Coya reports progress of first-in-class Treg-derived exosome program

Coya Therapeutics (NASDAQ:COYA) announced a status update of its investigational regulatory T cell-derived exosome—Treg exosomes—platform for the treatment of systemic and neurodegenerative diseases driven by chronic...

March 26, 2025

Developments

Sunshine enters agreement to market generic antibiotics in Canada

Sunshine Biopharma (NASDAQ:SBFM) announced that it has signed an agreement to market two new generic antibiotics in Canada through its wholly owned Canadian subsidiary, Nora Pharma, subject to regulatory approval...

March 25, 2025

Developments

Oncotelic completes Phase 1 study of OT-101 and IL-2 in metastatic solid tumors

Oncotelic Therapeutics (OTCQB:OTLC) announced it has completed Phase 1 of its trial evaluating OT-101 in combination with IL-2 for advanced metastatic tumors. According to Oncotelic, this announcement coincides with a...

March 25, 2025

Feature

Vivos transforming the lives of patients with obstructive sleep apnea

Vivos Therapeutics (NASDAQ:VVOS) is developing and commercializing innovative diagnostic and treatment methods for adult and pediatric patients suffering from sleep-related breathing disorders, including severe...

March 25, 2025

Developments

Can-Fite launches FDA/EMA-approved Phase 3 trial of Piclidenoson in psoriasis

Can-Fite BioPharma (NYSE American:CANF) announced that it has initiated a pivotal Phase 3 study of its oral drug Piclidenoson for the treatment of psoriasis, with FDA- and EMA-approved protocol. According to Can-Fite...

March 24, 2025

Author - Melane Sampson

Laurie Glimcher joins ReAlta’s BOD

MaaT Pharma advancing next frontier biotherapeutics with microbiome-driven therapies

Kazia agrees to sell Cantrixil IP and trademark rights to Vivesto

Neural shares commence trading on Frankfurt Stock Exchange

Leap reports positive Phase 2 data of sirexatamab in MSS CRC

Coya reports progress of first-in-class Treg-derived exosome program

Sunshine enters agreement to market generic antibiotics in Canada

Oncotelic completes Phase 1 study of OT-101 and IL-2 in metastatic solid tumors

Vivos transforming the lives of patients with obstructive sleep apnea

Can-Fite launches FDA/EMA-approved Phase 3 trial of Piclidenoson in psoriasis

Subscribe